» Articles » PMID: 28943923

Specific Expression of Proton-coupled Oligopeptide Transporter 1 in Primary Hepatocarcinoma-a Novel Strategy for Tumor-targeted Therapy

Overview
Journal Oncol Lett
Specialty Oncology
Date 2017 Sep 26
PMID 28943923
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Proton-coupled oligopeptide transporter 1 (PEPT1) is a membrane protein which expressed predominantly in intestine and recognized as the target of dietary nutrients (di/tripeptide) or peptidomimetic drug for delivery. The information on the existence of PEPT1 in carcinomas were limited. Our study aimed to investigate the expression profile and transport activity of PEPT1 both in human hepatocarcinoma tissues and cell lines. Western blotting and an immunofluorescence assay revealed the high level of PEPT1 protein expression in hepatocarcinoma Bel-7402, SMMC-7721, HepG2, HEP3B, SK-HEP-1 cell lines. Quantitative real time PCR showed the mRNA expression of PEPT1 in Bel-7402, SMMC-7721, HepG2, HEP3B, SK-HEP-1 cells. High level PEPT1 expression in hepatocarcinoma patient samples were observed by Immunohistology and showed a significant correlation between protein level and pathological grade. Functional activities were also studied using D-Ala-Lys-AMCA (a substrate of peptide transporter) in above five hepatocarcinoma cell lines. The uptake tests performed by fluorescent microscopy suggested that PEPT1 can transport both D-Ala-Lys-AMCA into the hepatocarcinoma cells and the uptake can be competitively inhibited by three PEPT1 substrates (Gly-sar, Gly-gln and Glyglygly). In conclusion, our findings provided the novel information on the expression and function of PEPT1 in human hepatocarcinoma and expanded the potential values for tumor specific drug delivery.

Citing Articles

Peptide Transporter 1-Mediated Dipeptide Transport Promotes Hepatocellular Carcinoma Metastasis by Activating MAP4K4/G3BP2 Signaling Axis.

Song F, Zhang Z, Liu W, Xu T, Hu X, Wang Q Adv Sci (Weinh). 2024; 11(24):e2306671.

PMID: 38639383 PMC: 11200092. DOI: 10.1002/advs.202306671.


PEPT1 is essential for the growth of pancreatic cancer cells: a viable drug target.

Schniers B, Rajasekaran D, Korac K, Sniegowski T, Ganapathy V, Bhutia Y Biochem J. 2021; 478(20):3757-3774.

PMID: 34569600 PMC: 8589330. DOI: 10.1042/BCJ20210377.


5-Aminolevulinic acid for fluorescence-guided surgery in pancreatic cancer: Cellular transport and fluorescence quantification studies.

Labib P, Yaghini E, Davidson B, MacRobert A, Pereira S Transl Oncol. 2020; 14(1):100886.

PMID: 33059124 PMC: 7566921. DOI: 10.1016/j.tranon.2020.100886.

References
1.
Gong X, Qin S . Progress in systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol. 2016; 22(29):6582-94. PMC: 4970483. DOI: 10.3748/wjg.v22.i29.6582. View

2.
Yuen M, Ahn S, Chen D, Chen P, Dusheiko G, Hou J . Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations. J Clin Gastroenterol. 2016; 50(4):286-94. DOI: 10.1097/MCG.0000000000000478. View

3.
Chen M, Singh A, Xiao F, Dringenberg U, Wang J, Engelhardt R . Gene ablation for PEPT1 in mice abolishes the effects of dipeptides on small intestinal fluid absorption, short-circuit current, and intracellular pH. Am J Physiol Gastrointest Liver Physiol. 2010; 299(1):G265-74. DOI: 10.1152/ajpgi.00055.2010. View

4.
Nielsen C, Brodin B . Di/tri-peptide transporters as drug delivery targets: regulation of transport under physiological and patho-physiological conditions. Curr Drug Targets. 2003; 4(5):373-88. DOI: 10.2174/1389450033491028. View

5.
Foltz M, Meyer A, Theis S, Demuth H, Daniel H . A rapid in vitro screening for delivery of peptide-derived peptidase inhibitors as potential drug candidates via epithelial peptide transporters. J Pharmacol Exp Ther. 2004; 310(2):695-702. DOI: 10.1124/jpet.104.066480. View